- Home
- FGEN vs STTK Comparison
FGEN vs STTK Comparison
Compare FGEN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- STTK
- Stock Information
- Founded
- FGEN 1993
- STTK 2016
- Country
- FGEN United States
- STTK United States
- Employees
- FGEN N/A
- STTK N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- STTK Health Care
- Exchange
- FGEN Nasdaq
- STTK Nasdaq
- Market Cap
- FGEN 33.5M
- STTK 37.6M
- IPO Year
- FGEN 2014
- STTK 2020
- Fundamental
- Price
- FGEN $5.30
- STTK $1.00
- Analyst Decision
- FGEN Strong Buy
- STTK Hold
- Analyst Count
- FGEN 1
- STTK 4
- Target Price
- FGEN $250.00
- STTK $3.00
- AVG Volume (30 Days)
- FGEN 53.3K
- STTK 112.0K
- Earning Date
- FGEN 08-05-2025
- STTK 07-31-2025
- Dividend Yield
- FGEN N/A
- STTK N/A
- EPS Growth
- FGEN N/A
- STTK N/A
- EPS
- FGEN N/A
- STTK N/A
- Revenue
- FGEN $6,996,000.00
- STTK $4,606,000.00
- Revenue This Year
- FGEN N/A
- STTK N/A
- Revenue Next Year
- FGEN N/A
- STTK N/A
- P/E Ratio
- FGEN N/A
- STTK N/A
- Revenue Growth
- FGEN N/A
- STTK 69.65
- 52 Week Low
- FGEN $4.50
- STTK $0.69
- 52 Week High
- FGEN $38.25
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- FGEN 31.98
- STTK 47.54
- Support Level
- FGEN $5.22
- STTK $0.91
- Resistance Level
- FGEN $5.85
- STTK $1.14
- Average True Range (ATR)
- FGEN 0.59
- STTK 0.08
- MACD
- FGEN -0.17
- STTK -0.01
- Stochastic Oscillator
- FGEN 4.72
- STTK 28.35
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.